186 results on '"Freeman, Samuel S."'
Search Results
2. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
3. Identification of transcriptional programs using dense vector representations defined by mutual information with GeneVector
4. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study
5. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer
6. Landscape of helper and regulatory antitumour CD4+ T cells in melanoma
7. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
8. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells
9. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia
10. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
11. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing
12. Identification and characterization of an alternative cancer-derived PD-L1 splice variant
13. Genomic and immune profiling of pre-invasive lung adenocarcinoma
14. Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response
15. Data from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1
16. Supplementary Figures and Tables from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1
17. Table S2 from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis
18. Supplementary Methods from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
19. Supplementary Figure Legends from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
20. Data from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
21. Data from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis
22. Supplementary Figures 1-4 from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
23. Supplementary Data from The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis
24. Supplementary Tables 1-8 from Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
25. Supplementary Figure 4 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
26. Supplementary Data from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
27. Supplementary Figure 1 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
28. Supplementary Figure 5 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
29. Supplementary Figure 8 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
30. Supplementary Figure 3 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
31. Supplementary Figure 9 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
32. Supplementary Figure 7 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
33. Supplementary Figure 6 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
34. Supplementary Tables from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
35. Supplementary Figure 2 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
36. Protocol for bulk RNA sequencing of enriched human neutrophils from whole blood and estimation of sample purity
37. Longitudinal characterization of circulating neutrophils uncovers phenotypes associated with severity in hospitalized COVID-19 patients
38. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing
39. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
40. Abstract 3610: In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer
41. Abstract 2259: Predictive modeling of smoldering multiple myeloma progression to multiple myeloma by continuous variable analysis
42. GeneVector: Identification of transcriptional programs using dense vector representations defined by mutual information
43. Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer
44. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma
45. Implementation of a prostate cancer‐specific targeted sequencing panel for credentialing of patient‐derived cell lines and genomic characterization of patient samples
46. Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women
47. Longitudinal characterization of circulating neutrophils uncovers distinct phenotypes associated with disease severity in hospitalized COVID-19 patients
48. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma
49. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells
50. The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.